Condition: Chronic Obstructive Pulmonary Disease · Sponsor: AstraZeneca
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Anhui, China | Recruiting |
| Research Site | Anning, China | Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Binzhou, China | Recruiting |
| Research Site | Changzhou, China | Recruiting |
| Research Site | Fenyang, China | Recruiting |
| Research Site | Guangdong, China | Recruiting |
| Research Site | Guangzhou, China | Recruiting |
| Research Site | Hangzhou, China | Recruiting |
| Research Site | Huzhou, China | Recruiting |
| Research Site | Jiaxing, China | Recruiting |
| Research Site | Jinan, China | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06862206